Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease
CJ Bailey, C Day, S Bellary - Current diabetes reports, 2022 - Springer
Abstract Purpose of Review This review offers a critical narrative evaluation of emerging
evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective …
evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective …
[HTML][HTML] Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care
The prevalence of type 2 diabetes and obesity has risen dramatically for decades and is
expected to rise further, secondary to the growing aging, sedentary population. The strain on …
expected to rise further, secondary to the growing aging, sedentary population. The strain on …
Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart …
Chronic kidney disease (CKD) with type 2 diabetes (T2D) is a major public health problem,
resulting in significant cardiovascular and kidney adverse outcomes worldwide. Despite the …
resulting in significant cardiovascular and kidney adverse outcomes worldwide. Despite the …
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
DSH Lin, JK Lee, CS Hung, WJ Chen - Diabetologia, 2021 - Springer
Aims/hypothesis Several cardiovascular outcome trials on sodium–glucose cotransporter 2
inhibitors (SGLT2i) have been released recently, including trials enrolling patients with …
inhibitors (SGLT2i) have been released recently, including trials enrolling patients with …
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
Approximately half of all patients with type 2 diabetes (T2D) develop a certain degree of
renal impairment. In many of them, chronic kidney disease (CKD) progresses over time …
renal impairment. In many of them, chronic kidney disease (CKD) progresses over time …
[HTML][HTML] 2023 clinical practice guidelines for diabetes management in Korea: full version recommendation of the Korean diabetes association
The 2023 Diabetes Clinical Practice Guidelines, developed by the Korean Diabetes
Association (KDA), aim to provide evidence-based recommendations for the diagnosis …
Association (KDA), aim to provide evidence-based recommendations for the diagnosis …
Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease
Importance Sodium-glucose cotransport protein 2 inhibitors (SGLT-2is) have demonstrated
associations with positive kidney-related and cardiovascular outcomes in patients with type …
associations with positive kidney-related and cardiovascular outcomes in patients with type …
Hyperkalemia: prevalence, predictors and emerging treatments
NL Larivée, JB Michaud, KM More, JA Wilson… - Cardiology and …, 2023 - Springer
It is well established that an elevated potassium level (hyperkalemia) is associated with a
risk of adverse events including morbidity, mortality and healthcare system cost …
risk of adverse events including morbidity, mortality and healthcare system cost …
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists
(GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular …
(GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular …
Anemia of cardiorenal syndrome
PA McCullough - Kidney International Supplements, 2021 - Elsevier
Cardiorenal syndrome includes a spectrum of disorders of the kidneys and heart in which
loss of function in one organ contributes to reduced function in the other organ. Cardiorenal …
loss of function in one organ contributes to reduced function in the other organ. Cardiorenal …